Should you buy Akba (Akba) stock in 2022?

In 2022, AKBA's revenue was $292.60 million, an increase of 37.00% compared to the previous year's $213.58 million. Losses were -$92.56 million, -67.27% less than in 2021. According to 2 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 138.10% from the latest price.

What was the 52-week low for Akebia Therapeutics stock?

The low in the last 52 weeks of Akebia Therapeutics stock was 0.24. According to the current price, Akebia Therapeutics is 435.68% away from the 52-week low. What was the 52-week high for Akebia Therapeutics stock? The high in the last 52 weeks of Akebia Therapeutics stock was 1.63.

What is the 12-month stock price forecast for akebia?

The 12-month stock price forecast is $3.0, which is an increase of 138.10% from the latest price. Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 20...